Liquid Biopsy For Personalised Monitoring Of Melanoma Patients
Funder
National Health and Medical Research Council
Funding Amount
$820,888.00
Summary
Despite the success of recent melanoma treatments, therapies are effective long term in only a proportion of patients. Here we will progress preliminary findings in collaboration with biotechnology and pathology companies to develop highly effective companion biomarkers that will aid treatment decisions throughout disease course. Our team will spearhead translation of these markers into the clinic for routine monitoring of melanoma patients.
CSI-Sydney: New Technologies To Treat Chronic Sinus Infection
Funder
National Health and Medical Research Council
Funding Amount
$412,213.00
Summary
Chronic sinus infection (CSI) is prevalent and results in severe discomfort and pain for many Australians; yet amazingly, has no specific cure or effective treatment. Our multi-disciplinary research team and an Australian health and medical research company, (AFT Pharmaceuticals) have partnered to develop a novel device that specifically targets the sinuses and a formulation capable for simultaneously removing mucus, dispersing biofilms and killing bacteria in the nasal cavities.
OctapeptinX Potentiators To Treat XDR Gram-negative Infections
Funder
National Health and Medical Research Council
Funding Amount
$1,377,149.00
Summary
There is an urgent need for the development of new antibiotics to treat drug-resistant infections, with the World Health Organisation and other agencies warning of a critical threat to human health. Potentiators are drugs that help obsolete antibiotics regain activity against resistant bacteria. We aim to develop a novel class of potentiators, the octapeptins, to resurrect the activity of old antibiotics so they can be used to treat infections caused by highly-resistant Gram-negative bacteria.
Improving Oocyte Mitochondrial DNA Copy Number To Enhance Female Reproductive Capacity.
Funder
National Health and Medical Research Council
Funding Amount
$670,867.00
Summary
Eggs with too few copies of mitochondrial DNA either fail to fertilise or arrest during early development. By supplementing eggs with mitochondrial DNA, we have been able to enhance embryo quality and gene expression profiles. By breeding the offspring derived from eggs given mitochondrial supplementation, we will determine if they and their progeny meet normal developmental milestones, regulate the transmission of mitochondrial DNA appropriately, and are healthy and fertile.
Low-Cost Portable Inhalation Therapy Platform For Needle-Free DNA-Based Influenza Vaccination
Funder
National Health and Medical Research Council
Funding Amount
$524,644.00
Summary
Influenza affects a large proportion of the global population and can result in many deaths in a pandemic. A DNA influenza vaccine overcomes the possibility of severe side effects associated with commonly used vaccines based on weakened viruses and can be rapidly produced and easily transported without refrigeration. DNA vaccines are however unstable and difficult to deliver. We propose to address this with a low-cost and portable handheld device which allows the vaccine to simply be inhaled.